Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
1. Amgen must pay $406 million to Regeneron for anticompetitive practices against Praluent.
FAQ
Why Very Bearish?
The $406 million liability could strain Amgen's finances. In prior cases, similar rulings negatively impacted biotech stocks.
How important is it?
The significant financial liability directly affects Amgen's stock valuation and investor confidence. Legal issues can lead to increased volatility.
Why Short Term?
The financial penalty will affect Amgen's short-term earnings and investor sentiment. Previous legal costs have impacted quarterly results quickly.